Searched for
BMS ABBOTT
NPPA not to stop withdrawal of stents from marketThe authority had asked the companies to consider options for price revision before deciding to withdraw their products from the market.- Price cap on stents opens the floodgates for new realitiesA cardiologist who spoke to ET on condition of anonymity said some companies, especially importers, have asked hospitals not to use stents ...
- Price caps will save patients nearly Rs1 lakh on cardiac stents: Ananth KumarThe move, which has upset domestic and multinational stent makers alike, would encourage companies to make in India to cut costs, the minis...
- Price of stent set to reduce as government includes two categories in NLEMThe National Pharmaceutical Pricing Authority—India's drug pricing watchdog—is expected to notify the new reset price for these stents.
- At last, India caps prices of stentsThe number of stent procedures in India trebled over the last five years, according to the National Interventional Council (NIC) registry 2...
- Top brokers recommend 'subscribe' to Syngene International IPO; here's whyLong-term investors should 'subscribe' to Syngene IPO which opens for subscription today, various brokerages said in a report.
- Syngene to be listed by August; IPO proceeds to be used for R&D: Kiran Mazumdar Shaw, BioconKiran Mazumdar Shaw, CMD, Biocon Ltd, tells us about the progress with the Syngene IPO and how the proceeds from the same will be used.
- Planning to list Syngene, selling stake part of IPO process: Kiran Mazumdar Shaw, Biocon'Syngene is India’s leading research services company in discovery and development space, especially in the pharmaceutical sector,' says Ma...
- Small molecule, API biz to be growth drivers for company: Kiran Mazumdar Shaw, Biocon"We have focused on creating key growth drivers and have structured the company along those growth drivers," says Kiran Mazumdar Shaw.
- Novartis patent verdict not a problem, other issues pose risks to Indian pharma innovationThe recent Supreme Court judgement against Novartis has reopened old debates on drug patents, affordable healthcare and India as a destinat...
- Bristol-Myers patent plea for HIV drug rejectedIndia has rejected American drugmaker Bristol-Myers Squibb's (BMS) patent application for one of its HIV drugs, allowing local drugmakers t...
Load More
